Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.32 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650036 | 0.89 | LMNA (0.30) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13725935 | 0.86 | — | — | |
| SCHEMBL13839392 | 0.86 | — | — | |
| SCHEMBL13650031 | 0.86 | — | — | |
| SCHEMBL13650039 | 0.85 | ENPP1 (0.32) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13839395 | 0.85 | ENPP1 (0.32) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13494110 | 0.84 | ADK (0.38) | LMNAALDH1A1TP53MAPTTDP1 | |
| SCHEMBL13650023 | 0.82 | LMNA (0.30) | LMNAALDH1A1 | |
| SCHEMBL13839396 | 0.81 | — | — | |
| SCHEMBL13650025 | 0.81 | ALDH1A1 (0.33) | LMNAALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7534771-B2 | Tricyclic-nucleoside prodrugs for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208457-A1 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections | PNP, TYMP, HAVCR2 | LMNA 1318/4885ALDH1A1 1203/4885TP53 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.